Pharmadrug Inc. (TSE:PHRX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
PharmaDrug Inc. has announced the appointment of Dr. David Kideckel, an experienced pharma industry executive, as the new Chairman of the Board, signaling a strategic move as the company advances its drug development programs. The company is poised for a ‘transformational’ year with progress in its PD-001 drug for oncology and infectious diseases, and advancements in biosynthetic pharmaceutical manufacturing through SecureDose. PharmaDrug’s subsidiary Sairiyo is moving forward with a Phase 1 clinical study in Australia for PD-001, leveraging the country’s R&D tax incentives.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.